BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Current Assets
Current assets not reported separately, such as prepaid expenses.
BioAge Labs, Inc.NASDAQ: BIOA
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 102.3% from a year ago
Other current assets stood at $7.96M at the end of Q1 FY2026, up 102.3% from a year earlier and up 61.5% from the prior quarter. Over 3 fiscal years it compounded at +133.7% a year.
Context
- Other current assets amounted to 2.0% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +102.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.93M USD
- Year-over-year change
- +78.9%
- 3-year CAGR
- +133.7%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.93M | +78.9% |
| FY2024 | 2024-12-31 | 2.75M | -24.8% |
| FY2023 | 2023-12-31 | 3.66M | +848.7% |
| FY2022 | 2022-12-31 | 386K | — |
Other Current Assets vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +102.3% is the 3rd highest of 9, against a peer median of +17.0%.
- Other current assets amounts to 2.0% of total assets for BIOA, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.82M USD | +1066.2% | — | 15.0% | |
| Mar 2026 | CA$13.14M CAD | +21.4% | +13.8% | 2.2% | |
| Mar 2026 | CA$9.49M CAD | +12.5% | -34.2% | 0.8% | |
BIOABioAge Labs, Inc. | Mar 2026 | $7.96M USD | +102.3% | +133.7% | 2.0% |
| Mar 2026 | $7.19M USD | -13.1% | -13.6% | 2.7% | |
| Mar 2026 | $5.68M USD | +105.4% | +32.1% | 3.8% | |
| Mar 2026 | $5.11M USD | -55.7% | -19.3% | 1.3% | |
| Mar 2026 | $4.7M USD | +100.2% | +12.5% | 4.3% | |
| Dec 2025 | $1.92M USD | — | — | 0.8% | |
| Mar 2026 | $1.83M USD | -45.8% | -34.4% | 1.2% | |
| Peer median (excluding BIOA) | — | +17.0% | -13.6% | 2.2% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.